Physician profile
Eric J Ormseth
NPI 1982686515
$8,715.02
in general payments reported to CMS, 2019-2025
36 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,729 · 2020: $346 · 2021: $522 · 2022: $2,215 · 2023: $1,926 · 2024: $1,256 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,065.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,491.06 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $562.58 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $353.89 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $333.63 | 2019-2023 | Rebyota |
| Janssen Biotech, INC. | $317.41 | 2019-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $314.43 | 2021-2023 | |
| Genzyme Corporation | $259.03 | 2022-2024 | |
| Celgene Corporation | $249.76 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $214.92 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $191.56 | 2021-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $165.48 | 2019-2025 | Axonics |
| Ardelyx, INC. | $153.12 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $121.93 | 2023-2025 | Omvoh |
| Medical Device Business Services, INC. | $114.84 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $99.79 | 2019-2023 | |
| Intuitive Surgical, INC. | $88.60 | 2019 | |
| Daiichi Sankyo INC. | $66.40 | 2019-2023 | Injectafer |
| Celltrion USA INC. | $63.62 | 2024-2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $56.83 | 2019-2023 | Dificid |
| Aimmune Therapeutics, INC. | $54.75 | 2024-2025 | Vowst |
| Evoke Pharma, INC. | $54.54 | 2022-2024 | Gimoti |
| Ucb, INC. | $52.20 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $41.25 | 2023-2025 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $32.17 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $31.70 | 2024 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $28.27 | 2024 | Lesionhunter |
| Amgen INC. | $23.23 | 2022 | |
| Astellas Pharma US INC | $17.84 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.35 | 2024 | Voquezna |
| Enterra Medical, INC. | $15.96 | 2023 | |
| Ambu INC. | $15.18 | 2022 | |
| Braintree Laboratories, INC. | $12.84 | 2019 | |
| Cook Medical LLC | $11.35 | 2020 | |
| Allergan, INC. | $11.18 | 2019 | |
| Redhill Biopharma INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ormseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.